Ulipristal Acetate CAS 126784-99-4 With Molecular Formula C30H37NO4

Product Description:

Product Name: Ulipristal Acetate CAS NO: 126784-99-4

Synonyms:

[(8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate;

VA2914;

Chemical & Physical Properties:

Appearance: White to beige powder

Assay :≥99.00%

Density: 1.19 g/cm3

Boiling Point: 640.1℃ at760mmHg

Melting Point: 183-185℃

Flash Point: 340.9℃

Refractive Index: 1.593

Vapor Pressure: 2.77E-16mmHg at 25℃

Safety Information:

Signal Word: Warning

Caution Statement: P280

Hazard Declaration: H361fd

Symbol: GHS08

Ulipristal acetate is a selective progesterone receptor modulator. Ulipristal acetate is used during pregnancy. Ulipristal acetate (UPA) is a selective progesterone receptor modulator. Attributing to its higher efficacy and a similar rate of side effects compared to levonorgestrel emergency contraception, it is now recommended as first line treatment for emergency contraception. Emergency contraception is defined as the use of drug or device after unprotected or under-protected intercourse to prevent an unwanted pregnancy. Ulipristal acetate can be used up to 5 days (120 h) after unprotected s-exual intercourse.

As progesterone promotes the growth of uterine fibroids, the blocking characteristic of ulipristal acetate can thereby be used to reduce the size of uterine fibroids. Ulipristal acetate has also shown efficacy with a significant reduction in uterine bleeding caused by uterine fibroids. The treatment of fibroids by ulipristal acetate should begin in the first week of a menstrual period.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.